Vanda Pharmaceuticals (NASDAQ: VNDA) today announced that the European Commission (EC) approved HETLIOZ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE